US2020376111A1PendingUtilityA1
Vaccine composition
Est. expiryApr 4, 2032(~5.7 yrs left)· nominal 20-yr term from priority
A61K 39/12A61K 39/39A61K 39/145A61K 39/395A61K 2039/55572A61P 31/12Y02A50/30A61K 2039/542A61K 2039/5258C12N 2760/16134A61K 2039/55561C12N 7/00A61K 2039/55516A61K 2039/541A61P 31/16C12N 2710/00034C12N 2760/16234A61P 37/04A61K 2039/575C12N 2760/16034A61P 31/00A61K 2039/5252
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2/6 (TLR2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof.
Claims
exact text as granted — not AI-modified1 . A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition comprising:
at least one antigen derived from an infectious disease, and a toll-like receptor 2/6 (TLR2/6) agonist comprising Pam 2 CSK 4 and salts thereof.
2 . The vaccine composition according to claim 1 , wherein:
the vaccine composition induces a mucosal immune response and a systemic immune response, the mucosal immune response is antigen-specific IgA antibody production, and the systemic immune response is antigen-specific IgG antibody production and antigen-specific cell-mediated immune production.
3 . The vaccine composition according to claim 1 , wherein the antigen derived from an infectious disease is an influenza virus-derived antigen.
4 . The vaccine composition according to claim 3 , wherein the influenza virus-derived antigen is hemagglutinin protein.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.